The American Psychological and Psychiatric Association (APPA) and BrainFutures have recently released the first set of professional practice guidelines for accepting, delivering, and monitoring psychedelic-assisted therapy. They result from a multi-year effort to provide comprehensive standards that can be used to ensure safe and effective treatment practices. This marks an important milestone in the development of psychedelic medicine, as practitioners now have a comprehensive set of guidelines to help them provide quality care.
The rationale behind APPA’s release of these guidelines is two-fold. First, by having standards in place before policymaking begins, researchers and clinicians are able to better educate policymakers on the science and evidence behind psychedelic-assisted therapy. This gives decision makers a clear understanding of the treatments available and the effects those policy decisions will have on patients and society.
Second, the guidelines provide a much-needed framework for practitioners to use when giving psychedelic-assisted therapies. They offer clear protocols for ensuring patient safety and consent, screening processes, ethics, and other important aspects of providing quality care. This helps to ensure that psychedelic-assisted therapies are delivered safely and effectively, thus allowing patients to achieve the best possible outcomes.
Benefits of the Guidelines
APPA’s guidelines offer a comprehensive set of standards for practitioners to use when providing psychedelic-assisted therapies. The guidelines cover topics such as prerequisites for training, patient screening processes, ethics, and safety protocols, among other important considerations. These protocols ensure that practitioners are qualified to provide these treatments safely and effectively while also protecting the rights of their patients.
The guidelines also have the intention of making psychedelic-assisted therapies more accessible to those who need them. By having clear protocols in place, practitioners can be confident that they are providing quality care and that their patients are receiving the best possible treatment. Additionally, by setting standards for training and patient screening processes, researchers will be better able to identify which individuals are likely to benefit from psychedelic-assisted therapies.
Finally, the guidelines also have the potential to shape future research and studies in the field of psychedelic medicine. By establishing a set of standards for delivering these treatments, researchers can be sure that their studies are being conducted in a safe and ethical manner. This will allow them to generate better data, which can then be used to refine or expand upon existing guidelines, furthering the development of this critical area of medicine.
Limitations and Challenges
While these newly released guidelines represent an important milestone for the field of psychedelic medicine, there are still several challenges that need to be addressed as oulined by the APPA. One of the most pressing issues is the limited amount of research available due to psychedelics being classified as Schedule I substances in the United States. This classification has stifled many studies and clinical trials by making it difficult for researchers to access these substances legally.
Another major challenge is the homogenous population of clinical trial volunteers. This has meant that much of the data used to generate these guidelines have come from a narrow range of individuals, limiting the perspectives and experiences that are taken into account when developing them. If psychedelic-assisted therapies become available to patients following FDA approval, they will likely be more diverse than those currently participating in clinical trials. This means that additional data and perspectives need to be gathered in order to ensure that the guidelines reflect the needs of this more diverse group of patients.
The release of APPA’s professional practice guidelines for psychedelic-assisted therapy marks an essential milestone in the normalization of psychedelic medicine. By providing comprehensive standards that address topics such as prerequisites for training, patient screening procedures, and safety protocols, these guidelines give practitioners a framework to ensure they provide quality care. They also have the potential to shape future research and studies in the field, as well as make psychedelic-assisted therapies more accessible to those who need them.
We hope that this is just the beginning of a more significant trend towards the normalization of psychedelic medicine. As research and clinical trials continue, we can expect to see an even greater understanding of these treatments’ potential benefits. With any luck, it won’t be long before anybody can choose to explore the potential of these powerful compounds.
Keep updated on all the latest news and updates in the Cannabis industry here at Beard Bros Pharms by signing up for our Friday Sesh Newsletter here. Always Dank and Never Spam!
